Serplulimab, a Chinese‐made intravenous PD‐1 monoclonal antibody, was the first PD‐1 monoclonal antibody to demonstrate efficacy and positive results in the treatment of SCLC.40 Here, PDCD1 is linked to small cell lung carcinoma.